Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Genaera Liquidating Trust (MEDI-528)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A portfolio of intellectual property rights. The portfolio includes certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca's subsidiary, MedImmune.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Products
Primary Office
  • 5110 Campus Drive
  • Plymouth Meeting, PA 19462
  • United States

Genaera Liquidating Trust (MEDI-528) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Genaera Liquidating Trust (MEDI-528)‘s full profile, request access.

Request full access to PitchBook

Genaera Liquidating Trust (MEDI-528) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Genaera Liquidating Trust (MEDI-528)‘s full profile, request access.

Request full access to PitchBook